Newsletter Tool

Today's Rundown

Biogen sends CEO to the exit, abandons Aduhelm sales team in $1B overhaul
Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to be
FDA plays tooth fairy, awards clearance to VideaHealth's cavity-spotting AI
OIG report reignites lawmakers' push for action on Medicare Advantage prior authorization
Pfizer sticks to guns on $22B Paxlovid sales despite reports of lagging demand
Kaufman Hall: Hospital outpatient volumes and revenue rebounds in March
FDA proposes order forcing Philips to repair, replace or refund all recalled ventilators
Another Pfizer gene therapy is free of FDA hold, but delay continues
Wearable, AI-powered whole-breast ultrasound system cleared by the FDA
Cerner's Q1 net earnings jump 20% as pending Oracle deal is expected to sail through EU antitrust review
AI researchers at Mayo Clinic use the Apple Watch to detect silent, weakening heart disease
Novartis’ Netflix moment? Big Pharma launches new on-demand video hub to boost digital engagement with doctors
Bad news from FDA prompts Spero to lay off 75% of staff, drop UTI drug

Featured Story

Biogen sends CEO to the exit, abandons Aduhelm sales team in $1B overhaul

By Angus Liu

Biogen’s yearlong struggle with the controversial FDA approval and launch of Aduhelm has culminated in a deep overhaul reaching all the way to the CEO.

Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to be

By Annalee Armstrong

Sierra Oncology was ready to take momelotinib to the market, but it needed help. What started as an effort to find a strategic partner turned into a $1.9 billion buyout from GlaxoSmithKline, which didn’t just want an arm's-length deal. Chief Commercial Officer Luke Miels wanted it all.

FDA plays tooth fairy, awards clearance to VideaHealth's cavity-spotting AI

By Andrea Park

The AI was built and trained using VideaHealth’s extensive database of dental X-rays, the Videa Factory, which the company says comprises the dental industry’s most diverse data set.

OIG report reignites lawmakers' push for action on Medicare Advantage prior authorization

By Robert King

A major new report from an HHS watchdog on prior authorization denials in Medicare Advantage sparked an urgent effort to get Congress to act on the issue.

Pfizer sticks to guns on $22B Paxlovid sales despite reports of lagging demand

By Fraiser Kansteiner

Paxlovid’s first-quarter revenue haul may look slim, but plenty more sales are on the way in the next three months, Pfizer executives said on an earnings call Tuesday. The Big Pharma said its COVID-19 oral antiviral, Paxlovid, could soon get a boost from contracts in China and Europe.

Kaufman Hall: Hospital outpatient volumes and revenue rebounds in March

By Robert King

Hospital and health system outpatient revenue and volumes rebounded in March after suffering major declines since the onset of the pandemic in 2020, Kaufman Hall reports.

FDA proposes order forcing Philips to repair, replace or refund all recalled ventilators

By Andrea Park

Seemingly still dissatisfied with Philips’ handling of its ongoing respiratory device recall, the FDA is now considering taking further action to force the medtech to tighten up its response to the safety event.

Another Pfizer gene therapy is free of FDA hold, but delay continues

By Gabrielle Masson

Another of Pfizer's gene therapies had been freed from an FDA clinical hold, but the study is not set to get underway immediately.

Wearable, AI-powered whole-breast ultrasound system cleared by the FDA

By Andrea Park

Scanning the entire breast volume with iSono's Atusa system takes only about one minute per side—a far cry from the 10 to 15 minutes it can take to complete manual probing.

Cerner's Q1 net earnings jump 20% as pending Oracle deal is expected to sail through EU antitrust review

By Heather Landi

Health IT giant Cerner brought in $206 million in net earnings for the first quarter of 2022, up 20% from $172 million during the same period a year ago. Software giant Oracle plans to buy the company in a $28 billion deal and said it would Cerner's business into more international markets. In the U.S. hospital market, Cerner continues to lose market share to competitor Epic.

PM Tracker

Featured Story

Biogen sends CEO to the exit, abandons Aduhelm sales team in $1B overhaul

Top Stories

Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to be

FDA plays tooth fairy, awards clearance to VideaHealth's cavity-spotting AI

OIG report reignites lawmakers' push for action on Medicare Advantage prior authorization

Pfizer sticks to guns on $22B Paxlovid sales despite reports of lagging demand

Kaufman Hall: Hospital outpatient volumes and revenue rebounds in March

FDA proposes order forcing Philips to repair, replace or refund all recalled ventilators

Another Pfizer gene therapy is free of FDA hold, but delay continues

Wearable, AI-powered whole-breast ultrasound system cleared by the FDA

Cerner's Q1 net earnings jump 20% as pending Oracle deal is expected to sail through EU antitrust review

AI researchers at Mayo Clinic use the Apple Watch to detect silent, weakening heart disease

Novartis’ Netflix moment? Big Pharma launches new on-demand video hub to boost digital engagement with doctors

Bad news from FDA prompts Spero to lay off 75% of staff, drop UTI drug